Human papilloma virus vaccines: Current scenario

Indian Journal of Sexually Transmitted Diseases

Volumn 32, Issue 2, 2011, Pages 75-85

  Pandhi, Deepika ^a   Sonthalia, Sidharth ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Cervical cancer; human papilloma virus vaccine; India; trials

Indexed keywords

STRUCTURAL PROTEIN; WART VIRUS VACCINE;

ALLERGIC REACTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANUS CANCER; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LACTATION; LONG TERM CARE; MORBIDITY; MORTALITY; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRECANCER; PREGNANCY; REVIEW; SEXUAL BEHAVIOR; SYNCOPE; TONIC CLONIC SEIZURE; TREATMENT CONTRAINDICATION; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER;

EID: 80053462232     PISSN: 02537184     EISSN: 19983816     Source Type: Journal    
DOI: 10.4103/0253-7184.85409     Document Type: Review

References (68)

1. WHO. Vaccines against human papillomavirus. Available from: http://www.who.int/vaccines/en/hpvrd.shtml/shtml/shtml. [Last accessed on 2011 June 4].
2. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: Disease, diagnosis, management, and prevention. Dermatol Ther 2010;23:458-76.
3. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-92.
4. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96-8.
5. Hsueh PR. Human papillomavirus, genital warts, and vaccines. J Microbiol Immunol Infect 2009;42:101-6.
6. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84:118-31.
7. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 Suppl 8:S4-66.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
9. Stanley M. Prophylactic HPV vaccines: Prospects for eliminating ano-genital cancer. Br J Cancer 2007;96:1320-3. (Pubitemid 46685776)
10. Muoz N, Bosch FX, de Sanjos S, Herrero R, Castellsagu X, Shah KV, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
11. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
12. Lu B, Kumar A, Castellsagu X, Giuliano AR. Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review and Meta- Analysis. BMC Infect Dis 2011;11:13.
13. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in India. Summary Report 2010. Available from: http://apps.who.int/hpvcentre/statistics/dynamic/ico/country- pdf/IND.pdf. [Last accessed on 2011 Jun 4].
14. Mariani L, Venuti A. HPV vaccine: An overview of immune response, clinical protection, and new approaches for the future. J Transl Med 2010;8:105.
15. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006;24(Suppl 3):S106-13. (Pubitemid 44293025)
16. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9. (Pubitemid 30416152)
17. Bosch FX, de Sanjose S. Chapter 1: Human papilloma virus and cervical cancer burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
18. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine. Vaccine 2007;25:4931-9. (Pubitemid 46843434)
19. Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomized clinical trials. Lancet 2007;369:1861-8. (Pubitemid 46829356)
20. Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck and Co, Inc: Food and Drug Administration 2009. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM094042. [Last accessed on 2011 Jun 4].
21. Food and Drug Administration. Product approval-prescribing information [package insert]. Cervarix [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant], GlaxoSmithKline Biologicals: Food and Drug Administration 2009. Available from: http://www.fda.gov/biologicsbloodvaccines/vaccines/ approvedproducts/ucm186957.htm. [Last accessed on 2011 Jun 4].
22. Merck USA. Highlights of prescribing information: GARDASIL [human papillomavirus quadrivalent (Types 6, 11, 16, and 18) vaccine, Recombinant], 2008. Available from: "http://www.merck.com/product/usa/pi-circulars/g/ Gardasil -pi.pdf. [Last accessed on 2011 Jun 4].
23. GlaxoSmithKline Australia. Cervarix product information: Human papillomavirus vaccine type 16 and 18 (Recombinant AS04 adjuvanted), 2007. Available from: http://www.gsk.com.au/resources.ashx/ vaccineproductschilddataproinfo/94/FileName/7A14FBAEA16635A2DD7A68ED78E8FDDC/ P1-Cervarix.pdf. [Last accessed on 2011 Jun 4].
24. The American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: Recommended childhood and adolescent immunization schedules - United States, 2010. Pediatrics 2010;125:195-6.
25. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2010;59:626-9.
26. Human papillomavirus (HPV) vaccine: A position statement of the Society for Adolescent Medicine. J Adolesc Health 2006;39:620.
27. Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Inte J Infect Dis 2007;11(Suppl 2):S17-25. (Pubitemid 350298917)
28. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71. (Pubitemid 46771257)
29. Schiller JT, Castellsagub X, Villac LL, Hildesheimd A. An Update of Prophylactic Human Papillomavirus L1 Virus-Like Particle Vaccine Clinical Trial Results. Vaccine 2008;26(Suppl 10):K53-61.
30. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 2010;341:c3493.
31. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmern J, Wheeler CM, et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
32. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. (Pubitemid 46740303)
33. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
34. Paavonen J, Naud P, Salmern J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus -16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
35. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66. (Pubitemid 44863348)
36. McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix ): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011;71:465-88.
37. Fraser C. Modelling the long-term antibody response of a human papillomavirus virus-like particle type 16 prophylactic vaccine. Vaccine 2007;25:4324-33. (Pubitemid 46635934)
38. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;10:705-19.
39. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007;3:109-15. (Pubitemid 47501028)
40. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
41. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-44.
42. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-25.
43. Poppe WA, Simon PH, De Ridder MR Why consider human papillomavirus vaccination in older women? Gynecol Obstet Invest 2010;70:237-43
44. Muoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 2009;373:1949-57.
45. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009;5:696-704.
46. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11.
47. Palefsky JM. Human papillomavirus-related disease in men: Not just a womens issue. J Adolesc Health 2010;46:Suppl:S12-9.
48. Palefsky JM. Efficacy of Gardasil in men aged 16-26 years naive to vaccine HPV types at baseline: The latest data. Paper presented at: Monte Carlo, Monaco: European Research Organisation on Genital Infection and Neoplasia Conference 2010.
49. Sturgis EM, Dahlstrom KR. HPV vaccination. Inaccurate assumptions about oropharyngeal cancer. BMJ 2009;339:b4525.
50. Nelson B. A new front in the debate over HPV vaccines for boys: Studies hint at broader benefits from Gardasil. Cancer Cytopathol 2010;118:413-4.
51. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246-53.
52. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, et al. IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010;55:197-204.
53. Segal L, Wilby OK, Willoughby CR, Veenstra S, Deschamps M. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 2011;31:111-20.
54. Forinash AB, Yancey AM, Pitlick JM, Myles TD. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy. Ann Pharmacother 2011; 45:258-62.
55. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: A systematic review of randomized controlled trials. CMAJ 2007;177:469-79. (Pubitemid 47359770)
56. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: A cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007;97:1322-8. (Pubitemid 350035812)
57. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review. Vaccine 2008,26:6258-65.
58. Goldie SJ, Oshea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV 16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008;16:86-96.
59. Choudhury P, John TJ. Human papilloma virus vaccines and current controversy. Indian Pediatr 2010;47:724-5.
60. Bharadwaj M, Hussain S, Nasare V, Das BC. HPV and HPV vaccination: Issues in developing countries. Indian J Med Res 2009;130:327-33.
61. Giri PA, Shirol SB, Kasbe AM. A comparative study to assess the knowledge and practices regarding sexual health among the migrants and non-migrants in Mumbai city. Int J Collab Res Intern Med Public Health 2011;3:341-52.
62. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet 2010;376:572-3.
63. Anon. Update: PATHSs HPV vaccine project in India. PATH. April 27, 2010. Available from: http://www.path.org/news/an100422-hpv-india.php. [Last accessed on 2011 Jun 4].
64. Sinha K. Four deaths not due to flawed cervical cancer vaccine trial. Times of India April 9, 2010. Available from: http://timesofindia.indiatimes. com/india/Four-deaths-not-due-to-flawed-cervical-cancer-vaccine-trial/ articleshow/5776065.cms. [Last accessed on 2011 Jun 4].
65. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 2006;66:11120-4. (Pubitemid 46009937)
66. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Mller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003;77:9211-20. (Pubitemid 37011018)
67. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch Virol 2003;148:1771-86. (Pubitemid 37144180)
68. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL, et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003;77:8702-11. (Pubitemid 36936081)